{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T15:04:08Z","timestamp":1768489448242,"version":"3.49.0"},"reference-count":16,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T00:00:00Z","timestamp":1497916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0179254","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T17:26:16Z","timestamp":1497979576000},"page":"e0179254","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Safety and tolerability of Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals\/antivirals (SCOLTA) project"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7608-6045","authenticated-orcid":true,"given":"Nicola","family":"Squillace","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Quirino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Bandera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Carenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Orofino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canio","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giordano","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetto Maurizio","family":"Celesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cordier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Vichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Calza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Falasca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Francesco","family":"Pellican\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the CISAI Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,6,20]]},"reference":[{"issue":"9835","key":"ref1","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"PE Sax","year":"2012","journal-title":"Lancet"},{"issue":"9835","key":"ref2","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"379","author":"E DeJesus","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"ref3","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S1473-3099(14)70796-0","article-title":"Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial","volume":"14","author":"A Pozniak","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"ref4","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(14)70782-0","article-title":"Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial","volume":"14","author":"JR Arribas","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000000476","article-title":"Elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment","volume":"68","author":"FA Post","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"18","key":"ref6","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1001\/archinte.162.18.2125","article-title":"Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects","volume":"162","author":"A De Luca","year":"2002","journal-title":"Arch Intern Med"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40261-016-0414-y","article-title":"Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?","volume":"36","author":"A Marcellusi","year":"2016","journal-title":"Clin Drug Investig"},{"key":"ref8","unstructured":"Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/rsc.tech-res.com\/docs\/default-source\/safety\/daids_ae_grading_table_v2_nov2014.pdf?sfvrsn=8\" xlink:type=\"simple\">https:\/\/rsc.tech-res.com\/docs\/default-source\/safety\/daids_ae_grading_table_v2_nov2014.pdf?sfvrsn=8<\/ext-link> [updated 2014; cited 2017 19 April 2017]."},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.biopha.2012.12.005","article-title":"Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project)","volume":"67","author":"B Menzaghi","year":"2013","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"ref10","first-page":"144","article-title":"Novel antiretroviral drugs and renal function monitoring of HIV patients","volume":"16","author":"P Maggi","year":"2014","journal-title":"AIDS Rev"},{"issue":"4","key":"ref11","first-page":"199","article-title":"Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management","volume":"16","author":"F Gutierrez","year":"2014","journal-title":"AIDS Rev"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40271-015-0129-9","article-title":"Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF","volume":"8","author":"A Mills","year":"2015","journal-title":"Patient"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s40271-015-0137-9","article-title":"Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF","volume":"8","author":"J Gathe","year":"2015","journal-title":"Patient"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M13-1829","article-title":"Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study","volume":"160","author":"V Lo Re 3rd","year":"2014","journal-title":"Ann Intern Med"},{"key":"ref15","article-title":"Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV","author":"A Mena","year":"2017","journal-title":"HIV Med"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/QAI.0000000000001069","article-title":"Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Alafenamide in HIV-1\/Hepatitis B-Coinfected Adults","volume":"73","author":"J Gallant","year":"2016","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0179254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T20:36:48Z","timestamp":1750365408000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0179254"}},"subtitle":[],"editor":[{"given":"D. William","family":"Cameron","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,6,20]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0179254","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,20]]}}}